CriticalClass Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver clears quinidine mainly through the enzyme CYP3A4, and quinidine levels rise, for example, with ketoconazole, probably because of competition for this pathway (quinidine label, US Food and Drug Administration, FDA). Voriconazole strongly inhibits CYP3A4 and can raise the levels of drugs broken down by this enzyme (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). No study has tested the pair. According to the voriconazole SmPC and label, higher quinidine levels can prolong the corrected QT interval (QTc) and, rarely, cause torsade de pointes (voriconazole SmPC, EMA, and label, FDA). Quinidine itself prolongs the QT interval in a dose-related way. The risk of torsade de pointes is higher with high quinidine blood levels, a slow heart rate and low potassium, magnesium or calcium (quinidine FDA label). QTc prolongation has also occurred with voriconazole (voriconazole SmPC, EMA).
Symptoms
Prolongation of the corrected QT interval (QTc) itself causes no symptoms and shows only on the electrocardiogram (ECG). Ventricular arrhythmias cause palpitations, dizziness or fainting. Life-threatening torsade de pointes, frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have been reported with quinidine (quinidine label, US Food and Drug Administration, FDA). Too much quinidine also causes low blood pressure, vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred and double vision, sensitivity to light, headache, confusion and delirium (quinidine FDA label). Rare cases of torsade de pointes, cardiac arrest and sudden death have occurred with voriconazole itself, usually in seriously ill patients with other risk factors (voriconazole FDA label).
Management
The combination is contraindicated. The voriconazole summaries of product characteristics (SmPCs) name quinidine among the drugs that must not be given with voriconazole. These drugs depend heavily on the enzyme CYP3A4 for their metabolism, and high levels of them are linked to serious or life-threatening reactions (voriconazole SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US voriconazole label also contraindicates quinidine, because its levels are likely to rise, with a risk of QT prolongation and rare torsade de pointes (voriconazole label, US Food and Drug Administration, FDA). The quinidine label does not mention voriconazole. According to it, drugs that change quinidine levels can cause toxicity or loss of effect unless the quinidine dose is adjusted (quinidine FDA label). Check potassium, magnesium and calcium before and during voriconazole treatment and correct them if needed (voriconazole SmPC, EMA, and label, FDA). The corrected QT interval (QTc) on the electrocardiogram (ECG) predicts quinidine-induced ventricular arrhythmias better than the quinidine blood level (quinidine FDA label). If the patient has nevertheless taken both drugs and develops haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine. Perform immediate cardioversion or, if a pacemaker is in place or immediately available, immediate overdrive pacing. Look for low potassium, magnesium and calcium and correct them actively (quinidine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage